ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:16 2024-06-28 EDT			5-day change	1st Jan Change
2.08 ^GBX	-2.35%		-6.09%	+24.78%

06-05	EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	AN
06-05	ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ImmuPharma Plc Announces Management Changes

May 06, 2015 at 02:02 am

ImmuPharma PLC announced that Dr. Franco Di Muzio, senior Non-Executive Director will take on the role of Chairman on an interim basis. Due to recent ill health, Richard Warr, Executive Chairman, has taken a leave of absence in order to make a full recovery.

Latest news about ImmuPharma plc

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	06-05	AN
ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	06-05	CI
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	04-29	CI
Immupharma jumps amid new IP strategy for P140 technology platform	04-02	AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	04-02	CI
Incanthera says first order from skincare deal doubles	03-25	AN
Stocks make tepid start to new week	03-25	AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	03-25	AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	03-06	AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	12-19	AN
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	12-19	MT
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	12-19	MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	12-19	CI
Incanthera signs skincare stocking deal, raises GBP1 million	12-18	AN
ImmuPharma plc Announces Executive Appointments	11-09	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	11-07	CI
RA International loss narrows as revenue grows	23-09-07	AN
British Biopharmaceutical Company ImmuPharma Closes Retail Offer of New Shares	23-09-07	MT
FTSE 100 Ends Negative Month on Subdued Note	23-08-31	DJ
ImmuPharma Targets GBP2 Million Equity Raise; Stock Sinks 12%	23-08-31	MT
ImmuPharma launches GBP2 million fund raise as interim loss narrows	23-08-31	AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959	23-08-31	MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25	23-08-31	MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
ImmuPharma agrees 12 month extension to Incanthera warrant instrument	23-08-21	AN

Chart ImmuPharma plc

Duration

Period

More charts

Company Profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+24.78%	10.95M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research